Quantification of the content of cannabidiol in commercially available e-liquids and studies on their thermal and photo-stability

[1]  B. Thomas,et al.  Labeling Accuracy of Cannabidiol Extracts Sold Online , 2017, JAMA.

[2]  J. Nonnemaker,et al.  Youth use of electronic vapor products and blunts for administering cannabis. , 2017, Addictive behaviors.

[3]  IfflandKerstin,et al.  An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies , 2017 .

[4]  Michael H. Nantz,et al.  Aldehyde Detection in Electronic Cigarette Aerosols , 2017, ACS omega.

[5]  A. Fletcher,et al.  Cross-sectional study examining the prevalence, correlates and sequencing of electronic cigarette and tobacco use among 11–16-year olds in schools in Wales , 2017, BMJ Open.

[6]  J. Metts,et al.  Recreational cannabinoid use: The hazards behind the "high". , 2016, The Journal of family practice.

[7]  M. R. Peace,et al.  Evaluation of Two Commercially Available Cannabidiol Formulations for Use in Electronic Cigarettes , 2016, Front. Pharmacol..

[8]  L. Walker,et al.  Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents , 2016, Pharmacotherapy.

[9]  Ron Borland,et al.  Electronic Nicotine Delivery System , 2015 .

[10]  R. Laprairie,et al.  Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor , 2015, British journal of pharmacology.

[11]  Andrzej Sobczak,et al.  Carbonyl compounds in electronic cigarette vapors: effects of nicotine solvent and battery output voltage. , 2014, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[12]  M. Elsohly,et al.  Constituents of Cannabis Sativa , 2014 .

[13]  R. Capasso,et al.  Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. , 2009, Trends in pharmacological sciences.

[14]  R. Pertwee,et al.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin , 2008 .

[15]  R. Mechoulam,et al.  Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. , 2002, Chemistry and physics of lipids.

[16]  Raphael Mechoulam,et al.  Cannabidiol: An Overview of Some Pharmacological Aspects , 2002, Journal of clinical pharmacology.

[17]  E. Russo.  Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential , 2002 .

[18]  J. McPartland,et al.  Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts? , 2001 .

[19]  P. Consroe.  Brain Cannabinoid Systems as Targets for the Therapy of Neurological Disorders , 1998, Neurobiology of Disease.

[20]  E LeBourdais,et al.  Greater than the sum of their parts. , 1986, Canadian doctor.

[21]  L. Hollister,et al.  Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. , 1986, Biomedical & environmental mass spectrometry.

[22]  Kerstin Iffland.  European Industrial Hemp Association ( EIHA ) review on : Safety and Side Effects of Cannabidiol – A review of clinical data and relevant animal studies , 2016 .

[23]  Laurentiu Filipescu,et al.  The Influence of Long-term Storage Conditions on the Stability of Cannabinoids derived from Cannabis Resin , 2012 .

[24]  R. Adams,et al.  Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild Hemp. I , 1940 .